Navigation Links
Aton Pharma Announces Distribution Partnership in Brazil
Date:5/12/2008

LAWRENCEVILLE, N.J., May 12 /PRNewswire/ -- Aton Pharma, Inc., a global specialty pharmaceutical company, announced today that it has signed a distribution agreement with Meizler Biopharma S/A to commercialize CUPRIMINE(R) and SYPRINE(R) in Brazil. Cuprimine is currently approved in Brazil, and Meizler is working to obtain regulatory approval of Syprine.

"Cuprimine and Syprine are medically essential products, and Aton is committed to making these products available wherever they are needed," said Michael G. Wells, Chief Executive Officer of Aton Pharma. "Brazil is the largest country in Latin America, and we are very pleased that we found Meizler to help us address the needs of patients in this country."

"Meizler has a long history of providing important medical therapies in Brazil," stated Avi Meizler, Meizler's President. "Cuprimine and Syprine both perfectly complement our current portfolio, and we look forward to helping Aton expand their presence in Brazil."

Meizler is a Brazilian Pharmaceutical company, headquartered in Sao Paulo, active in both the out-patient and hospital segments of the pharmaceutical industry. The company currently markets more than 40 products on the Brazilian market and has international partnerships in place with companies in the United States, Europe and Asia, to which Meizler provides various regulatory and commercial services. Using an advanced management and logistics system, Meizler is able to rapidly supply its high quality products to providers and patients. For more information, see http://www.meizler.com.br.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global specialty pharmaceutical company providing essential treatments for under- treated diseases and rare illnesses around the world. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of seven products, with sales in over 30 countries, targets rare and orphan metabolic, neurological, cardiovascular and ophthalmic diseases. For more information, see http://www.atonrx.com.

CONTACT: Ed Stevens, 727-327-3396, Estevens3@tampabay.rr.com


'/>"/>
SOURCE Aton Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmasset Selected to Join the NASDAQ Biotechnology Index
2. Tianyin Pharmaceutical to Present at the Brean Murray All-Cap All-China Conference in New York City on May 20, 2008 at 10:15 a.m. EDT
3. NuRx Pharmaceuticals Announces Change of Ticker Symbol to NUXP, Reverse Stock Split Now in Effect
4. Amylin Pharmaceuticals to Present at Baird Growth Stock Conference
5. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
6. Celator(R) Pharmaceuticals Announces Appointment of Scott Jackson as CEO
7. EUSA Pharma Completes Acquisition Of Cytogen Corporation
8. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
9. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
11. Onyx Pharmaceuticals to Present at Bank of America Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... -RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" ... clinical data from its phase 1/2 tendon repair study investigating ... (RCT-01) as a treatment for Achilles tendinosis. ... The clinical trial ... 6 months and showed no serious adverse events related to ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... fight against cancer, autoimmune disease and more through a single-cell precision engineering platform, ... proteomics analysis platform developed in the laboratory of Dr. James Heath at ...
(Date:3/27/2017)... , March 27, 2017  The global ... for 2016, according to a new report from ... lab testing is performed to evaluate disease progression, ... therapy, among other reasons.  The healthcare market research ... , provides an overview of the medical ...
(Date:3/27/2017)... ... March 27, 2017 , ... A research team ... vascular grafts in JoVE’s Video Journal, the world’s first peer-reviewed scientific video journal. ... of treating coronary artery disease (CAD). Lam is an assistant professor at the ...
Breaking Biology Technology:
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
(Date:2/28/2017)... Feb. 28, 2017   Acuant , a leading ... announces significant enhancements to new and core technologies building ... products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity documents ... provides the fastest and most accurate capture software to ...
(Date:2/28/2017)... Spanien, 27. Februar 2017  EyeLock LLC, ein marktführendes ... seine erstklassige biometrische Lösung zur Iris-Erkennung auf ... X16 LTE auf dem Mobile World Congress ... Qualcomm-Stand in Halle 3, Stand 3E10, vorstellen. ... Sicherheitsplattform Qualcomm Haven™ – eine Kombination aus ...
Breaking Biology News(10 mins):